Prescription profiles for pharmacological treatment of Japanese inpatients with schizophrenia: Comparison between 2007 and 2009

Takashi Yoshio, Toshiya Inada, Junji Uno, Takaichi Miwa, Kohei Kitagawa, Yoshiki Miyahara, Kenta Umeda, Tsuyoshi Kato, Ataru Inagaki, Toshitaka Nabeshima

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background and Objective Pharmacological treatment of schizophrenic patients in Japan is characterized by polypharmacy with high doses of antipsychotics. In this study, we examined the profiles of antipsychotic drug therapy in 2007 and 2009 to determine if there have been any recent shifts in treatment strategy. Method The subjects were schizophrenic inpatients (ICD-10-F20) admitted to 100 hospitals in 2007 and 152 hospitals in 2009. Information on the psychotropic agents prescribed on specified days in November 2007 and 2009 was acquired for each patient. Results Although no changes were observed in the rate of antipsychotic medications being prescribed, the rate of antipsychotic monotherapy in 2009 increased significantly. In 2007, among 15,761 patients, 4977 (31.6%) received antipsychotic monotherapy (i.e., administration of a single antipsychotic medication). In 2009, among 22,911 patients, 7741 (33.8%) received antipsychotic monotherapy. Conclusion The rate of use of antipsychotic monotherapy has gradually increased, although the total dose has not changed significantly. The increase in the concomitant use of two or more second-generation antipsychotics is a recent trend in Japan, despite the lack of information on the efficacy and safety of this treatment strategy.

Original languageEnglish
Pages (from-to)70-75
Number of pages6
JournalHuman Psychopharmacology
Volume27
Issue number1
DOIs
Publication statusPublished - 01-01-2012
Externally publishedYes

Fingerprint

Antipsychotic Agents
Prescriptions
Inpatients
Schizophrenia
Pharmacology
Therapeutics
Japan
Polypharmacy
International Classification of Diseases
Safety
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Yoshio, Takashi ; Inada, Toshiya ; Uno, Junji ; Miwa, Takaichi ; Kitagawa, Kohei ; Miyahara, Yoshiki ; Umeda, Kenta ; Kato, Tsuyoshi ; Inagaki, Ataru ; Nabeshima, Toshitaka. / Prescription profiles for pharmacological treatment of Japanese inpatients with schizophrenia : Comparison between 2007 and 2009. In: Human Psychopharmacology. 2012 ; Vol. 27, No. 1. pp. 70-75.
@article{b1804fb0526f473aa5b3a48153a7f676,
title = "Prescription profiles for pharmacological treatment of Japanese inpatients with schizophrenia: Comparison between 2007 and 2009",
abstract = "Background and Objective Pharmacological treatment of schizophrenic patients in Japan is characterized by polypharmacy with high doses of antipsychotics. In this study, we examined the profiles of antipsychotic drug therapy in 2007 and 2009 to determine if there have been any recent shifts in treatment strategy. Method The subjects were schizophrenic inpatients (ICD-10-F20) admitted to 100 hospitals in 2007 and 152 hospitals in 2009. Information on the psychotropic agents prescribed on specified days in November 2007 and 2009 was acquired for each patient. Results Although no changes were observed in the rate of antipsychotic medications being prescribed, the rate of antipsychotic monotherapy in 2009 increased significantly. In 2007, among 15,761 patients, 4977 (31.6{\%}) received antipsychotic monotherapy (i.e., administration of a single antipsychotic medication). In 2009, among 22,911 patients, 7741 (33.8{\%}) received antipsychotic monotherapy. Conclusion The rate of use of antipsychotic monotherapy has gradually increased, although the total dose has not changed significantly. The increase in the concomitant use of two or more second-generation antipsychotics is a recent trend in Japan, despite the lack of information on the efficacy and safety of this treatment strategy.",
author = "Takashi Yoshio and Toshiya Inada and Junji Uno and Takaichi Miwa and Kohei Kitagawa and Yoshiki Miyahara and Kenta Umeda and Tsuyoshi Kato and Ataru Inagaki and Toshitaka Nabeshima",
year = "2012",
month = "1",
day = "1",
doi = "10.1002/hup.1272",
language = "English",
volume = "27",
pages = "70--75",
journal = "Human Psychopharmacology",
issn = "0885-6222",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

Yoshio, T, Inada, T, Uno, J, Miwa, T, Kitagawa, K, Miyahara, Y, Umeda, K, Kato, T, Inagaki, A & Nabeshima, T 2012, 'Prescription profiles for pharmacological treatment of Japanese inpatients with schizophrenia: Comparison between 2007 and 2009', Human Psychopharmacology, vol. 27, no. 1, pp. 70-75. https://doi.org/10.1002/hup.1272

Prescription profiles for pharmacological treatment of Japanese inpatients with schizophrenia : Comparison between 2007 and 2009. / Yoshio, Takashi; Inada, Toshiya; Uno, Junji; Miwa, Takaichi; Kitagawa, Kohei; Miyahara, Yoshiki; Umeda, Kenta; Kato, Tsuyoshi; Inagaki, Ataru; Nabeshima, Toshitaka.

In: Human Psychopharmacology, Vol. 27, No. 1, 01.01.2012, p. 70-75.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prescription profiles for pharmacological treatment of Japanese inpatients with schizophrenia

T2 - Comparison between 2007 and 2009

AU - Yoshio, Takashi

AU - Inada, Toshiya

AU - Uno, Junji

AU - Miwa, Takaichi

AU - Kitagawa, Kohei

AU - Miyahara, Yoshiki

AU - Umeda, Kenta

AU - Kato, Tsuyoshi

AU - Inagaki, Ataru

AU - Nabeshima, Toshitaka

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Background and Objective Pharmacological treatment of schizophrenic patients in Japan is characterized by polypharmacy with high doses of antipsychotics. In this study, we examined the profiles of antipsychotic drug therapy in 2007 and 2009 to determine if there have been any recent shifts in treatment strategy. Method The subjects were schizophrenic inpatients (ICD-10-F20) admitted to 100 hospitals in 2007 and 152 hospitals in 2009. Information on the psychotropic agents prescribed on specified days in November 2007 and 2009 was acquired for each patient. Results Although no changes were observed in the rate of antipsychotic medications being prescribed, the rate of antipsychotic monotherapy in 2009 increased significantly. In 2007, among 15,761 patients, 4977 (31.6%) received antipsychotic monotherapy (i.e., administration of a single antipsychotic medication). In 2009, among 22,911 patients, 7741 (33.8%) received antipsychotic monotherapy. Conclusion The rate of use of antipsychotic monotherapy has gradually increased, although the total dose has not changed significantly. The increase in the concomitant use of two or more second-generation antipsychotics is a recent trend in Japan, despite the lack of information on the efficacy and safety of this treatment strategy.

AB - Background and Objective Pharmacological treatment of schizophrenic patients in Japan is characterized by polypharmacy with high doses of antipsychotics. In this study, we examined the profiles of antipsychotic drug therapy in 2007 and 2009 to determine if there have been any recent shifts in treatment strategy. Method The subjects were schizophrenic inpatients (ICD-10-F20) admitted to 100 hospitals in 2007 and 152 hospitals in 2009. Information on the psychotropic agents prescribed on specified days in November 2007 and 2009 was acquired for each patient. Results Although no changes were observed in the rate of antipsychotic medications being prescribed, the rate of antipsychotic monotherapy in 2009 increased significantly. In 2007, among 15,761 patients, 4977 (31.6%) received antipsychotic monotherapy (i.e., administration of a single antipsychotic medication). In 2009, among 22,911 patients, 7741 (33.8%) received antipsychotic monotherapy. Conclusion The rate of use of antipsychotic monotherapy has gradually increased, although the total dose has not changed significantly. The increase in the concomitant use of two or more second-generation antipsychotics is a recent trend in Japan, despite the lack of information on the efficacy and safety of this treatment strategy.

UR - http://www.scopus.com/inward/record.url?scp=84856321088&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856321088&partnerID=8YFLogxK

U2 - 10.1002/hup.1272

DO - 10.1002/hup.1272

M3 - Article

C2 - 22249957

AN - SCOPUS:84856321088

VL - 27

SP - 70

EP - 75

JO - Human Psychopharmacology

JF - Human Psychopharmacology

SN - 0885-6222

IS - 1

ER -